MEI Pharma (MEI Pharma) EBIT : $22.44 Mil (TTM As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is MEI Pharma EBIT?

MEI Pharma's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-9.83 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $22.44 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MEI Pharma's annualized ROC % for the quarter that ended in Mar. 2024 was -252.00%. MEI Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -324.12%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MEI Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -88.02%.

MEI Pharma EBIT Historical Data

The historical data trend for MEI Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma EBIT Chart

MEI Pharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

-46.25

-25.70

-60.42

-75.48

-36.76

MEI Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-16.39	-11.08	55.28	-11.93	-9.83

Competitive Comparison of MEI Pharma's EBIT

For the Biotechnology subindustry, MEI Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MEI Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MEI Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MEI Pharma's EV-to-EBIT falls into.

MEI Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.44 Mil.

MEI Pharma (NAS:MEIP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MEI Pharma's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-39.316 * ( 1 - 0% )	/	( (15.617	+	15.586)	/ 2 )
=	-39.316	/	15.6015
=	-252.00 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	78.538	-	4.787	-	( 59.48	-	max(0, 8.038	-	66.172	+	59.48	))
=	15.617

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	71.26	-	5.924	-	( 56.552	-	max(0, 9.616	-	59.366	+	56.552	))
=	15.586

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

MEI Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-39.316	/	( ( (12.366 + max(-0.331, 0))	+	(11.894 + max(-5.75, 0)) )	/	2 )
=	-39.316	/	( ( 12.366	+	11.894 )	/	2 )
=	-39.316	/	12.13
=	-324.12 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.692)	-	(4.787	+	0	+	2.236)
=	-0.331

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.814)	-	(5.924	+	0	+	2.64)
=	-5.75

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MEI Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	22.442	/	-25.496
	=	-88.02 %

MEI Pharma EBIT Related Terms

Thank you for viewing the detailed overview of MEI Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (MEI Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (NAS:MEIP) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

0JW9:UK

Address

11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Executives

Taheer Datoo	director	181 BAY STREET, SUITE 4200, TORONTO A6 M5J 2T3
James P Flynn	director	41 HARRIS CT, DANVILLE CA 94526
Sujay Kango	director	1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Richard G Ghalie	officer: Chief Medical Officer	C/O FAVRILLE, INC, 10445 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Bruce Ross Winson	10 percent owner	5950 BERKSHIRE LANE, SUITE 510, DALLAS TX 75225
Anson Funds Management Lp	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Management Gp Llc	10 percent owner	16000 DALLAS PARKWAY, SUITE 800, DALLAS TX 75248
Anson Advisors Inc.	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO A6 M5H 3B7
Funicular Funds, Lp	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Amin Nathoo	10 percent owner	155 UNIVERSITY AVENUE, SUITE 207, TORONTO Z4 M5H 3B7
Moez Kassam	10 percent owner	111 PETER STREET, SUITE 904, TORONTO A6 M5V2H1
Justin J. File	officer: CFO and Corporate Secretary	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Jacob Ma-weaver	10 percent owner	2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114
Cable Car Capital Llc	10 percent owner	2261 MARKET STREET #4307, SAN FRANCISCO CA 94114
Baltic Charles V. Iii	director	C/O MARSHALL EDWARDS, INC., 11975 EL CAMINO REAL, SUITE 101, SAN DIEGO CA 92130